{"id":6249,"date":"2025-12-11T10:44:33","date_gmt":"2025-12-11T10:44:33","guid":{"rendered":"https:\/\/sahelib.atatec-design.com\/index.php\/2025\/12\/11\/evaluation-de-programmes-de-prevention-en-sante-publique\/"},"modified":"2025-12-11T11:47:10","modified_gmt":"2025-12-11T11:47:10","slug":"evaluation-de-programmes-de-prevention-en-sante-publique","status":"publish","type":"post","link":"https:\/\/sahelib.atatec-design.com\/index.php\/2025\/12\/11\/evaluation-de-programmes-de-prevention-en-sante-publique\/","title":{"rendered":"\u00c9valuation de programmes de pr\u00e9vention en sant\u00e9 publique"},"content":{"rendered":"<h2>\u00c9valuation de programmes de pr\u00e9vention en sant\u00e9 publique<\/h2>\n<p><strong>Auteur(s) :<\/strong> Dr. Fatou Ndiaye \u2014 <strong>Date :<\/strong> 2021-09-13 \u2014 <strong>Source :<\/strong> SpringerLink<\/p>\n<h2 data-start=\"444\" data-end=\"457\"><strong data-start=\"447\" data-end=\"457\">R\u00e9sum\u00e9<\/strong><\/h2>\n<p data-start=\"459\" data-end=\"1263\">L\u2019\u00e9valuation des programmes de pr\u00e9vention en sant\u00e9 publique constitue un \u00e9l\u00e9ment cl\u00e9 pour mesurer l\u2019efficacit\u00e9 des interventions, optimiser les ressources et guider les politiques de sant\u00e9. Cet article pr\u00e9sente une synth\u00e8se des m\u00e9thodes d\u2019\u00e9valuation, des indicateurs utilis\u00e9s et des principaux r\u00e9sultats obtenus dans diff\u00e9rents contextes de pr\u00e9vention primaire, secondaire et tertiaire. Nous discutons des approches quantitatives, qualitatives et mixtes, de l\u2019importance de l\u2019adaptation contextuelle, et des d\u00e9fis li\u00e9s \u00e0 la collecte de donn\u00e9es et \u00e0 la durabilit\u00e9 des interventions. Enfin, une analyse comparative de programmes internationaux permet d\u2019identifier les facteurs cl\u00e9s de succ\u00e8s et les limites rencontr\u00e9es, offrant des recommandations pour renforcer l\u2019impact des initiatives de sant\u00e9 publique.<\/p>\n<p data-start=\"1265\" data-end=\"1379\"><strong data-start=\"1265\" data-end=\"1280\">Mots-cl\u00e9s :<\/strong> \u00e9valuation, programmes de pr\u00e9vention, sant\u00e9 publique, indicateurs, efficacit\u00e9, revue syst\u00e9matique.<\/p>\n<hr data-start=\"1381\" data-end=\"1384\" \/>\n<h2 data-start=\"1386\" data-end=\"1401\"><strong data-start=\"1389\" data-end=\"1401\">Abstract<\/strong><\/h2>\n<p data-start=\"1403\" data-end=\"2092\">The evaluation of public health prevention programs is a critical component for assessing intervention effectiveness, optimizing resource allocation, and informing health policy. This article provides a comprehensive review of evaluation methods, key indicators, and outcomes across primary, secondary, and tertiary prevention contexts. We discuss quantitative, qualitative, and mixed-method approaches, the importance of contextual adaptation, and challenges related to data collection and intervention sustainability. A comparative analysis of international programs identifies success factors and limitations, offering recommendations to enhance the impact of public health initiatives.<\/p>\n<p data-start=\"2094\" data-end=\"2201\"><strong data-start=\"2094\" data-end=\"2107\">Keywords:<\/strong> evaluation, prevention programs, public health, indicators, effectiveness, systematic review.<\/p>\n<hr data-start=\"2203\" data-end=\"2206\" \/>\n<h2 data-start=\"2208\" data-end=\"2227\"><strong data-start=\"2211\" data-end=\"2227\">Introduction<\/strong><\/h2>\n<p data-start=\"2229\" data-end=\"2441\">La pr\u00e9vention en sant\u00e9 publique vise \u00e0 r\u00e9duire l\u2019incidence et la gravit\u00e9 des maladies \u00e0 travers des interventions cibl\u00e9es sur la population. Les programmes de pr\u00e9vention peuvent \u00eatre class\u00e9s en trois cat\u00e9gories :<\/p>\n<ol data-start=\"2443\" data-end=\"2867\">\n<li data-start=\"2443\" data-end=\"2553\">\n<p data-start=\"2446\" data-end=\"2553\"><strong data-start=\"2446\" data-end=\"2471\">Pr\u00e9vention primaire :<\/strong> pr\u00e9vention de l\u2019apparition des maladies (ex. vaccination, campagnes d\u2019hygi\u00e8ne).<\/p>\n<\/li>\n<li data-start=\"2554\" data-end=\"2678\">\n<p data-start=\"2557\" data-end=\"2678\"><strong data-start=\"2557\" data-end=\"2584\">Pr\u00e9vention secondaire :<\/strong> d\u00e9pistage pr\u00e9coce pour limiter la progression de la maladie (ex. mammographies, tests VIH).<\/p>\n<\/li>\n<li data-start=\"2679\" data-end=\"2867\">\n<p data-start=\"2682\" data-end=\"2867\"><strong data-start=\"2682\" data-end=\"2708\">Pr\u00e9vention tertiaire :<\/strong> r\u00e9duction des complications et am\u00e9lioration de la qualit\u00e9 de vie pour les patients atteints de maladies chroniques (ex. programmes de r\u00e9adaptation cardiaque).<\/p>\n<\/li>\n<\/ol>\n<p data-start=\"2869\" data-end=\"3027\">L\u2019efficacit\u00e9 de ces programmes d\u00e9pend non seulement de la qualit\u00e9 de l\u2019intervention mais \u00e9galement de leur \u00e9valuation syst\u00e9matique. L\u2019\u00e9valuation permet de :<\/p>\n<ul data-start=\"3028\" data-end=\"3220\">\n<li data-start=\"3028\" data-end=\"3082\">\n<p data-start=\"3030\" data-end=\"3082\">Mesurer les impacts sanitaires et comportementaux.<\/p>\n<\/li>\n<li data-start=\"3083\" data-end=\"3140\">\n<p data-start=\"3085\" data-end=\"3140\">Identifier les facteurs facilitants et les obstacles.<\/p>\n<\/li>\n<li data-start=\"3141\" data-end=\"3220\">\n<p data-start=\"3143\" data-end=\"3220\">Justifier l\u2019allocation des ressources et orienter les d\u00e9cisions politiques.<\/p>\n<\/li>\n<\/ul>\n<p data-start=\"3222\" data-end=\"3470\">Cet article vise \u00e0 fournir un \u00e9tat des connaissances sur les m\u00e9thodes d\u2019\u00e9valuation, les indicateurs utilis\u00e9s et les r\u00e9sultats obtenus, tout en proposant une analyse comparative des programmes internationaux pour en d\u00e9gager les meilleures pratiques.<\/p>\n<hr data-start=\"3472\" data-end=\"3475\" \/>\n<h2 data-start=\"3477\" data-end=\"3519\"><strong data-start=\"3480\" data-end=\"3519\">\u00c9tat de l\u2019art et revue syst\u00e9matique<\/strong><\/h2>\n<h3 data-start=\"3521\" data-end=\"3582\"><strong data-start=\"3525\" data-end=\"3582\">1. M\u00e9thodes d\u2019\u00e9valuation des programmes de pr\u00e9vention<\/strong><\/h3>\n<h4 data-start=\"3584\" data-end=\"3620\"><strong data-start=\"3589\" data-end=\"3620\">1.1 \u00c9valuation quantitative<\/strong><\/h4>\n<ul data-start=\"3621\" data-end=\"3861\">\n<li data-start=\"3621\" data-end=\"3702\">\n<p data-start=\"3623\" data-end=\"3702\">Mesure des effets sur la sant\u00e9 : incidence, pr\u00e9valence, mortalit\u00e9, morbidit\u00e9.<\/p>\n<\/li>\n<li data-start=\"3703\" data-end=\"3765\">\n<p data-start=\"3705\" data-end=\"3765\">\u00c9tudes exp\u00e9rimentales : essais contr\u00f4l\u00e9s randomis\u00e9s (ECR).<\/p>\n<\/li>\n<li data-start=\"3766\" data-end=\"3861\">\n<p data-start=\"3768\" data-end=\"3861\">\u00c9tudes quasi-exp\u00e9rimentales : comparaisons avant-apr\u00e8s ou avec groupe t\u00e9moin non randomis\u00e9.<\/p>\n<\/li>\n<\/ul>\n<h4 data-start=\"3863\" data-end=\"3898\"><strong data-start=\"3868\" data-end=\"3898\">1.2 \u00c9valuation qualitative<\/strong><\/h4>\n<ul data-start=\"3899\" data-end=\"4115\">\n<li data-start=\"3899\" data-end=\"3965\">\n<p data-start=\"3901\" data-end=\"3965\">Analyse des perceptions des b\u00e9n\u00e9ficiaires et des intervenants.<\/p>\n<\/li>\n<li data-start=\"3966\" data-end=\"4014\">\n<p data-start=\"3968\" data-end=\"4014\">\u00c9tudes de cas et entretiens semi-structur\u00e9s.<\/p>\n<\/li>\n<li data-start=\"4015\" data-end=\"4115\">\n<p data-start=\"4017\" data-end=\"4115\">Identification des obstacles culturels, sociaux et organisationnels \u00e0 l\u2019adh\u00e9sion aux programmes.<\/p>\n<\/li>\n<\/ul>\n<h4 data-start=\"4117\" data-end=\"4146\"><strong data-start=\"4122\" data-end=\"4146\">1.3 Approches mixtes<\/strong><\/h4>\n<ul data-start=\"4147\" data-end=\"4370\">\n<li data-start=\"4147\" data-end=\"4234\">\n<p data-start=\"4149\" data-end=\"4234\">Combinaison des m\u00e9thodes quantitatives et qualitatives pour une \u00e9valuation globale.<\/p>\n<\/li>\n<li data-start=\"4235\" data-end=\"4370\">\n<p data-start=\"4237\" data-end=\"4370\">Exemple : \u00e9valuation de programmes de vaccination combinant couverture vaccinale (quantitatif) et acceptabilit\u00e9 sociale (qualitatif).<\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"4372\" data-end=\"4375\" \/>\n<h3 data-start=\"4377\" data-end=\"4412\"><strong data-start=\"4381\" data-end=\"4412\">2. Indicateurs d\u2019\u00e9valuation<\/strong><\/h3>\n<p data-start=\"4414\" data-end=\"4506\">Les indicateurs utilis\u00e9s dans l\u2019\u00e9valuation se regroupent en trois cat\u00e9gories principales :<\/p>\n<ol data-start=\"4508\" data-end=\"4873\">\n<li data-start=\"4508\" data-end=\"4633\">\n<p data-start=\"4511\" data-end=\"4633\"><strong data-start=\"4511\" data-end=\"4541\">Indicateurs d\u2019efficacit\u00e9 :<\/strong> r\u00e9duction de l\u2019incidence des maladies, taux de d\u00e9pistage, am\u00e9lioration des comportements.<\/p>\n<\/li>\n<li data-start=\"4634\" data-end=\"4743\">\n<p data-start=\"4637\" data-end=\"4743\"><strong data-start=\"4637\" data-end=\"4667\">Indicateurs de processus :<\/strong> respect du protocole, taux de participation, qualit\u00e9 de la mise en \u0153uvre.<\/p>\n<\/li>\n<li data-start=\"4744\" data-end=\"4873\">\n<p data-start=\"4747\" data-end=\"4873\"><strong data-start=\"4747\" data-end=\"4797\">Indicateurs de satisfaction et acceptabilit\u00e9 :<\/strong> perception des b\u00e9n\u00e9ficiaires et des prestataires, engagement communautaire.<\/p>\n<\/li>\n<\/ol>\n<hr data-start=\"4875\" data-end=\"4878\" \/>\n<h3 data-start=\"4880\" data-end=\"4939\"><strong data-start=\"4884\" data-end=\"4939\">3. Analyse comparative de programmes internationaux<\/strong><\/h3>\n<h4 data-start=\"4941\" data-end=\"5009\"><strong data-start=\"4946\" data-end=\"5009\">3.1 Programme de vaccination contre la rougeole (OMS, 2018)<\/strong><\/h4>\n<ul data-start=\"5010\" data-end=\"5213\">\n<li data-start=\"5010\" data-end=\"5101\">\n<p data-start=\"5012\" data-end=\"5101\">R\u00e9sultat : r\u00e9duction de 80 % de l\u2019incidence dans les pays \u00e0 haute couverture vaccinale.<\/p>\n<\/li>\n<li data-start=\"5102\" data-end=\"5213\">\n<p data-start=\"5104\" data-end=\"5213\">Facteurs de succ\u00e8s : campagnes communautaires, communication cibl\u00e9e et suivi des indicateurs de couverture.<\/p>\n<\/li>\n<\/ul>\n<h4 data-start=\"5215\" data-end=\"5280\"><strong data-start=\"5220\" data-end=\"5280\">3.2 Programme de d\u00e9pistage du cancer colorectal (Europe)<\/strong><\/h4>\n<ul data-start=\"5281\" data-end=\"5436\">\n<li data-start=\"5281\" data-end=\"5356\">\n<p data-start=\"5283\" data-end=\"5356\">R\u00e9sultat : d\u00e9tection pr\u00e9coce et r\u00e9duction de la mortalit\u00e9 jusqu\u2019\u00e0 30 %.<\/p>\n<\/li>\n<li data-start=\"5357\" data-end=\"5436\">\n<p data-start=\"5359\" data-end=\"5436\">Limites : disparit\u00e9s r\u00e9gionales dans l\u2019adh\u00e9sion et le suivi post-d\u00e9pistage.<\/p>\n<\/li>\n<\/ul>\n<h4 data-start=\"5438\" data-end=\"5519\"><strong data-start=\"5443\" data-end=\"5519\">3.3 Programmes de pr\u00e9vention du diab\u00e8te de type 2 (\u00c9tats-Unis, Finlande)<\/strong><\/h4>\n<ul data-start=\"5520\" data-end=\"5742\">\n<li data-start=\"5520\" data-end=\"5626\">\n<p data-start=\"5522\" data-end=\"5626\">R\u00e9sultat : diminution de 25 \u00e0 40 % du risque de d\u00e9velopper la maladie dans les cohortes \u00e0 haut risque.<\/p>\n<\/li>\n<li data-start=\"5627\" data-end=\"5742\">\n<p data-start=\"5629\" data-end=\"5742\">Facteurs de succ\u00e8s : interventions comportementales individualis\u00e9es, suivi longitudinal et soutien communautaire.<\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"5744\" data-end=\"5747\" \/>\n<h2 data-start=\"5749\" data-end=\"5766\"><strong data-start=\"5752\" data-end=\"5766\">Discussion<\/strong><\/h2>\n<p data-start=\"5768\" data-end=\"5848\">L\u2019analyse comparative montre que les programmes les plus efficaces combinent :<\/p>\n<ul data-start=\"5849\" data-end=\"6211\">\n<li data-start=\"5849\" data-end=\"5919\">\n<p data-start=\"5851\" data-end=\"5919\">Une <strong data-start=\"5855\" data-end=\"5883\">mise en \u0153uvre rigoureuse<\/strong>, bas\u00e9e sur des protocoles clairs.<\/p>\n<\/li>\n<li data-start=\"5920\" data-end=\"6025\">\n<p data-start=\"5922\" data-end=\"6025\">Une <strong data-start=\"5926\" data-end=\"5953\">adaptation contextuelle<\/strong>, prenant en compte les sp\u00e9cificit\u00e9s culturelles et socio-\u00e9conomiques.<\/p>\n<\/li>\n<li data-start=\"6026\" data-end=\"6107\">\n<p data-start=\"6028\" data-end=\"6107\">Une <strong data-start=\"6032\" data-end=\"6059\">\u00e9valuation syst\u00e9matique<\/strong>, utilisant des indicateurs clairs et fiables.<\/p>\n<\/li>\n<li data-start=\"6108\" data-end=\"6211\">\n<p data-start=\"6110\" data-end=\"6211\">Une <strong data-start=\"6114\" data-end=\"6152\">participation communautaire active<\/strong>, favorisant l\u2019adh\u00e9sion et la durabilit\u00e9 des interventions.<\/p>\n<\/li>\n<\/ul>\n<p data-start=\"6213\" data-end=\"6385\">Les d\u00e9fis r\u00e9currents incluent la collecte de donn\u00e9es de qualit\u00e9, les biais d\u2019\u00e9chantillonnage, les contraintes financi\u00e8res et la durabilit\u00e9 \u00e0 long terme des effets observ\u00e9s.<\/p>\n<hr data-start=\"6387\" data-end=\"6390\" \/>\n<h2 data-start=\"6392\" data-end=\"6425\"><strong data-start=\"6395\" data-end=\"6425\">Conclusion et perspectives<\/strong><\/h2>\n<p data-start=\"6427\" data-end=\"7064\">L\u2019\u00e9valuation des programmes de pr\u00e9vention en sant\u00e9 publique est essentielle pour guider les d\u00e9cisions politiques et optimiser les interventions. Les m\u00e9thodes mixtes, combinant mesures quantitatives et analyses qualitatives, apparaissent les plus adapt\u00e9es pour comprendre \u00e0 la fois l\u2019efficacit\u00e9 sanitaire et les d\u00e9terminants sociaux. Les programmes internationaux \u00e9tudi\u00e9s d\u00e9montrent que l\u2019adh\u00e9sion communautaire et l\u2019adaptation contextuelle sont des facteurs cl\u00e9s de succ\u00e8s. Les perspectives futures incluent l\u2019utilisation accrue des technologies num\u00e9riques pour le suivi en temps r\u00e9el, l\u2019analyse pr\u00e9dictive et l\u2019\u00e9valuation participative.<\/p>\n<hr data-start=\"7066\" data-end=\"7069\" \/>\n<h2 data-start=\"7071\" data-end=\"7114\"><strong data-start=\"7074\" data-end=\"7114\">R\u00e9f\u00e9rences scientifiques (s\u00e9lection)<\/strong><\/h2>\n<ol data-start=\"7116\" data-end=\"7991\">\n<li data-start=\"7116\" data-end=\"7214\">\n<p data-start=\"7119\" data-end=\"7214\">World Health Organization (2018). <strong data-start=\"7153\" data-end=\"7198\">Global Measles and Rubella Strategic Plan<\/strong>. Geneva: WHO.<\/p>\n<\/li>\n<li data-start=\"7215\" data-end=\"7403\">\n<p data-start=\"7218\" data-end=\"7403\">Wolf AMD, Fontham ETH, Church TR, et al. (2018). <strong data-start=\"7267\" data-end=\"7345\">Colorectal cancer screening for average-risk adults: 2018 guideline update<\/strong>. <em data-start=\"7347\" data-end=\"7384\">CA: A Cancer Journal for Clinicians<\/em>, 68(4): 250\u2013281.<\/p>\n<\/li>\n<li data-start=\"7404\" data-end=\"7629\">\n<p data-start=\"7407\" data-end=\"7629\">Tuomilehto J, Lindstr\u00f6m J, Eriksson JG, et al. (2001). <strong data-start=\"7462\" data-end=\"7575\">Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance<\/strong>. <em data-start=\"7577\" data-end=\"7610\">New England Journal of Medicine<\/em>, 344: 1343\u20131350.<\/p>\n<\/li>\n<li data-start=\"7630\" data-end=\"7795\">\n<p data-start=\"7633\" data-end=\"7795\">Victora CG, Habicht JP, Bryce J. (2004). <strong data-start=\"7674\" data-end=\"7739\">Evidence-based public health: moving beyond randomized trials<\/strong>. <em data-start=\"7741\" data-end=\"7776\">American Journal of Public Health<\/em>, 94(3): 400\u2013405.<\/p>\n<\/li>\n<li data-start=\"7796\" data-end=\"7991\">\n<p data-start=\"7799\" data-end=\"7991\">Glasgow RE, Vogt TM, Boles SM. (1999). <strong data-start=\"7838\" data-end=\"7933\">Evaluating the public health impact of health promotion interventions: the RE-AIM framework<\/strong>. <em data-start=\"7935\" data-end=\"7970\">American Journal of Public Health<\/em>, 89(9): 1322\u20131327.<\/p>\n<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>\u00c9valuation de programmes de pr\u00e9vention en sant\u00e9 publique Auteur(s) : Dr. Fatou Ndiaye \u2014 Date : 2021-09-13 \u2014 Source : SpringerLink R\u00e9sum\u00e9 L\u2019\u00e9valuation des programmes de pr\u00e9vention en sant\u00e9 publique constitue un \u00e9l\u00e9ment cl\u00e9 pour mesurer l\u2019efficacit\u00e9 des interventions, optimiser les ressources et guider les politiques de sant\u00e9. Cet article pr\u00e9sente une synth\u00e8se des m\u00e9thodes [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":6315,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[111,110],"tags":[],"class_list":["post-6249","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medecine-biotechnologies","category-sante-publique"],"acf":[],"_links":{"self":[{"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/posts\/6249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/comments?post=6249"}],"version-history":[{"count":1,"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/posts\/6249\/revisions"}],"predecessor-version":[{"id":6317,"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/posts\/6249\/revisions\/6317"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/media\/6315"}],"wp:attachment":[{"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/media?parent=6249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/categories?post=6249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sahelib.atatec-design.com\/index.php\/wp-json\/wp\/v2\/tags?post=6249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}